A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease
This is a study to learn if a study medicine can help prevent Respiratory Syncytial Virus (RSV) infection in babies who are more likely to get severe RSV illness.
Principal Investigator: